Amy Hont, M.D., is an attending physician in the Department of Hematology/Oncology and physician-scientist in the Center for Cancer and Immunology Research. Her research interest focuses on the use of targeted therapies, including immunotherapy, for patients with high-risk malignancies. In particular she investigates the optimization of adoptive cell therapy for patients with relapsed or refractory solid tumor, including modification of T cell products and the tumor microenvironment.